• Shuoshan Wang, Xiansheng Yang, Chang Liu, Jinlun Hu, Mei Yan, Chan Ding, and Yue Fu.
• Department of General Medicine, The First People's Hospital of Foshan, The Affiliated Foshan Hospital of Sun Yat-Sen University, Guangdong, China.
• Medicine (Baltimore). 2023 Oct 6; 102 (40): e35111e35111.

BackgroundGastric cancer (GC) is highly biologically and genetically heterogeneous disease with poor prognosis. Increasing evidence indicates that biomarkers can serve as prediction and clinical intervention. Therefore, it is vital to identify core molecules and pathways participating in the development of GC.MethodsIn this study, GSE54129, GSE56807, GSE63089, and GSE118916 were used for identified overlapped 75 DEGs. GO and Kyoto Encyclopedia of Genes and Genomes pathway analysis showed DEGs mainly enriched in biological process about collagen-containing extracellular matrix and collagen metabolic. Next, protein-protein interaction network was built and the hub gene was excavated. Clinicopathological features and prognostic value were also evaluated.ResultsHub genes were shown as below, FN1, COL1A2, COL1A1, COL3A1, COL4A1, COL6A3, COL5A2, SPARC, PDGFRB, COL12A1. Those genes were upregulation in GC and related to the poor prognosis (except COL5A2, P = .73). What is more, high expression indicated worse T stage and tumor, node, metastasis stage in GC patients. Later, the results of 25 GC tumor specimens and 34 normal tissues showed that FN1, COL3A1, COL4A1, SPARC, COL5A2, and COL12A1 were significantly upregulated in cancer samples.ConclusionOur study systematically explored the core genes and crucial pathways in GC, providing insights into clinical management and individual treatment.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…